Macclesfield, UK – 26 January 2026 – MedChemica is part of a new global initiative, funded by the Gates Foundation, Novo Nordisk, and Wellcome, aimed at combating antimicrobial resistance (AMR) driven by a specific group of bacteria responsible for the majority of AMR-related deaths. The Gram-negative Antibiotic Discovery Innovator (Gr-ADI) focuses on data-sharing and
Every drug hunting project needs its own IP strategy but the current purely market-driven approaches to drug discovery and development alone are insufficient to drive equitable access to new therapies either in preparation for, or in response to, pandemics. Following the experiences gained from the COVID Moonshot program and the ASAP AViDD drug discovery
On Wednesday 18th May the NIH announced that the team that led the COVID Moonshot, including ourselves at MedChemica, along with additional collaborators has been awarded an initial $68 million to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics caused by RNA viruses. The award is for
How do you sort out a P450 inhibition problem? I had honestly forgotten about contributing to a book chapter, when the email came through that it was finally published. “Strategies to Mitigate CYP450 Inhibition” was co-written with Marcel de Groot and Sarah Skerratt several months ago. Of course, it went through editing and joining to
© 2026 Medchemica | All rights reserved | Designed & Built by Greenlight Web